Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs aimed at addressing medical challenges that other drug modalities cannot effectively tackle [3] Group 1: Company Overview - Molecular Partners AG is listed on both SIX and NASDAQ under the ticker MOLN and was founded in 2004 [3] - The company has its headquarters in Zurich, Switzerland, and an office in Concord, Massachusetts, USA [3] - The primary focus of the company is oncology, with various programs in different stages of pre-clinical and clinical development [3] Group 2: Upcoming Events - The CEO, Patrick Amstutz, will present the latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2025, from 10:30 AM to 11:10 AM PT [2] - A webcast of the presentation will be available on the Molecular Partners website under the Events tab [2] Group 3: Strategic Partnerships - Molecular Partners collaborates with leading pharmaceutical companies to leverage the advantages of DARPins and provide unique solutions to patients [3]